Houston energy tech startup incubator secures federal support to accelerate tech entrepreneurship

seeing green

Greentown Houston has received funding from the EDA. Photo via GreentownLabs.com

Sixty organizations across the country have received a grant from the United States Department of Commerce — and one recipient is based in Houston.

Greentown Labs, dual located in Houston and Somerville, Massachusetts, has received a grant from the 10th cohort of the Economic Development Administration's “Build to Scale” program for its Houston location. The $53 million of funding was awarded to 60 organizations across 36 states, the District of Columbia, and Puerto Rico. All of the programs support technology entrepreneurs across industries.

“The Biden-Harris Administration is Investing in America to help create entrepreneurial ecosystems across the country and put quality, 21st century job opportunities in people’s backyards,” Secretary of Commerce Gina Raimondo says in the press release. “The ‘Build to Scale’ program will unlock innovation potential in regions all over the nation, improving our economic competitiveness now, and for decades to come.”

According to the EDA, Greentown, located in a growing innovation district, will receive $400,000 with a $400,000 local match confirmed. The project, named Houston Ion District Investor Activation, is described as a way to create economic opportunity through equitable capital access.

"This project capitalizes on the need for jobs and economic development, especially in communities most vulnerable to the impacts of natural disasters," reads the project abstract. "EDA funding will enable the expansion of Greentown’s Investor Program into EDIJ, in partnership with the Ion, to further climate equity and resilience in Houston and empower underrepresented entrepreneurs as the city transitions from fossil fuels to a clean energy economy."

Greentown receives of of the 2023 Capital Challenge Grant Recipients. The other competition, the Venture Challenge, also awarded funding to another Houston organization. The Urban Partnerships Community Development Corporation received $741,925 to support the BioWell Start Accelerator Program, which is committed to scaling of bio-industrial startups.

“EDA is proud to partner with this year’s ‘Build to Scale’ grantees as they fuel regional innovation hubs and technology-based economic development strategies throughout the U.S.,” Assistant Secretary of Commerce for Economic Development Alejandra Y. Castillo says in the release. “Investing in scalable startups and expanding access entrepreneurial capital will yield good-paying jobs, economic resiliency, and equitable growth in communities throughout America.”

------

This article originally ran on EnergyCapital.

From Your Site Articles
The Ion has fresh funds to commit to its accelerator programs. Courtesy of Rice University

The Ion receives $1.5M economic development grant to go toward Houston accelerator programs

accelerating accelerators

The Ion — a rising hub for innovation being developed in Midtown by Rice Management Company — has received a $1.5 million grant to go toward supporting its startup accelerator programs.

The grant from the Economic Development Administration is a part of the organization's Build to Scale (B2S) program and will also benefit three accelerators: the Ion Smart and Resilient Cities Accelerator, the Rice Alliance Clean Energy Accelerator, and DivInc Accelerator.

"Receiving this grant is a big win for our city — furthering the Ion's opportunity to bring together leading minds to solve some of our toughest challenges," says Brad Burke, managing director of the Rice Alliance, in a news release from Rice. "We believe that it's a fully collaborative approach that will lead to accelerating energy innovation and sustainable solutions."

All three of these accelerators will be represented in The Ion's Accelerator Hub and will work in collaboration, according to the release, in The Ion, which is expected to open in 2021 with cohorts set to open applications in early 2021.

"We are really excited about working together with DivInc and the Rice Alliance for Technology and Entrepreneurship to realize the full potential of the opportunities that these funds will help unleash," says Jan Odegard, interim executive director of the Ion, in the release.

The Ion Smart and Resilient Cities Accelerator has cycled through two rounds of cohorts — first focusing on resilience and mobility in Cohort 1 then air quality, water purification, and other cleantech in Cohort 2.

The 12-week Clean Energy Accelerator was only recently announced by The Rice Alliance for Technology and Entrepreneurship at the annual Energy Tech Venture Forum earlier this month. The program is established to support Houston Mayor Sylvester Turner's Climate Action Plan.

Meanwhile, DivInc's accelerator comes out of a partnership with the Austin-based nonprofit and The Ion, which was announced in spring of this year. The goal with this program is to increase access to minority entrepreneurs.

"DivInc embodies the mindset that this generation and all the generations of innovators to follow must be inclusive of people of color and women entrepreneurs – who will build successful scalable growth companies to address tomorrow's challenges and opportunities," says Preston James, chief executive officer at DivInc, in the release.

"By removing the barriers that currently exist, we unleash this untapped potential and lift Houston to new economic heights. To do this we must establish strong collaboration with partners like The Ion, Rice University, the EDA and many others."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings